4//SEC Filing
Browne L Daniel 4
Accession 0001479290-18-000002
CIK 0001479290other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 8:13 PM ET
Size
5.8 KB
Accession
0001479290-18-000002
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Other
Common Stock
2017-12-29$22.99/sh+127$2,920→ 133,315 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]These shares were acquired by Mr. Browne under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 29, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Browne purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2017.
- [F2]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001597583
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 8:13 PM ET
- Size
- 5.8 KB